Pharmaceuticals, Biotechnology and Life Sciences
Diplomat Pharmacy, has entered into a definitive agreement to acquire Pharmaceutical Technologies, doing business as National Pharmaceutical Services. The transaction…
Diplomat Pharmacy will dispense newly approved Eli Lilly’s Verzenio(abemaciclib), a twice-daily oral therapy for advanced breast cancer. Verzenio is indicated…
Diplomat Pharmacy will distribute Puma Biotechnology’s new product, Nerlynx, a kinase inhibitor approved by the US Food and Drug Administration (FDA).
Diplomat Pharmacy will distribute Zejula (niraparib) for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Diplomat Pharmacy and Corizon Health have entered into three-year agreement according to which Diplomat will provide pharmacy services and dispense limited-distribution specialty drugs for Corizon Health’s clients and support its in-house mail-order pharmacy, PharmaCorr
Diplomat Pharmacy has appointed Atul Kavthekar as chief financial officer and treasurer, effective May 1, 2017.
Diplomat Pharmacy will distribute Novartis’s newly approved breast cancer drug Kisqali (ribociclib) as a first-line treatment for postmenopausal women with a serious form of the disease.
Lexicon Pharmaceuticals’ Xermelo was recently approved with orphan status by the Food and Drug Administration (FDA) and Diplomat, the USA largest independent specialty pharmacy, will fill prescriptions for it, as it has been selected to the limited-distribution panel of the drug.
TALTZ was recently approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe plaque psoriasis.
Nearly 50 percent of Medicaid patients infected with chronic hepatitis C virus (HCV) whose doctors had prescribed newer, life-saving antiviral drugs were denied coverage to the therapies because they were not considered “a medical necessity.”